# US 2014/0271788 A1 · Sublingual and buccal film compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271788 A1
- Document ID: US20140271788A1
- Status: Published application
- Kind: A1
- Application number: 13/842,543
- Filed: 2013-03-15
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: Monosol Rx, LLC
- Inventors: Garry L. Myers; Eric Dadey
- Web page: https://patentgrep.com/patent/US20140271788A1

## CPC

- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/36: Opioid-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

## Claims

### Claim 1

A self-supporting film dosage composition comprising:
a. A polymeric carrier matrix;
b. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof;
c. a buffer sufficient to maximize the absorption of the agonist; and
d. a chelator or an antioxidant.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 4 (depends on 1)

The composition of claim 1, wherein said agonist is a partial agonist.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said agonist is an opioid agonist.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said composition has a local pH of about 4 to about 9.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising a therapeutically effective amount of an antagonist or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said composition comprises a first and a second region, said first region comprising said agonist and said second region comprising said antagonist.

### Claim 9 (depends on 8)

The composition of claim 8, wherein said first region has a local pH of about 4 to about 9.

### Claim 10 (depends on 9)

The composition of claim 9, wherein said local pH is about 5.5.

### Claim 11 (depends on 8)

The composition of claim 8, wherein said second region has a local pH of about 2 to about 4.

### Claim 12 (depends on 11)

The composition of claim 11, wherein said local pH is about 2.

### Claim 13 (depends on 1)

The composition of claim 1, wherein said polymeric carrier matrix comprises at least one polymer in an amount of at least 25% by weight of said composition.

### Claim 14 (depends on 1)

The composition of claim 1, wherein said buffer is present in an amount of from about 2:1 to about 1:5 buffer to agonist.

### Claim 15 (depends on 1)

The composition of claim 1, wherein said composition comprises at least one self-supporting film-forming polymer.

### Claim 16 (depends on 1)

The film dosage composition of claim 1, wherein said agonist is present in an amount of from about 2 mg to about 16 mg per dosage.

### Claim 17 (depends on 1)

The film dosage composition of claim 1, wherein said buffer comprises sodium citrate, citric acid, and combinations thereof.

### Claim 18 (depends on 1)

The film dosage composition of claim 1, wherein said buffer comprises acetic acid, sodium acetate, and combinations thereof.

### Claim 19

A self-supporting film dosage composition comprising:
a. A polymeric carrier matrix;
b. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof;
c. A therapeutically effective amount of an antagonist or a pharmaceutically acceptable salt thereof;
d. A buffering system; and
e. A chelator or an antioxidant;
wherein said buffering system comprises a buffer capacity sufficient to inhibit the absorption of said antagonist during the time which said composition is in the oral cavity of a user.

### Claim 20 (depends on 17)

The composition of claim 17, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 21 (depends on 17)

The composition of claim 17, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 22 (depends on 19)

The composition of claim 19, wherein said agonist is a partial agonist.

### Claim 23 (depends on 19)

The composition of claim 19, wherein said agonist is an opioid agonist.

### Claim 24 (depends on 19)

The composition of claim 19, wherein said composition comprises a first region and a second region, said first region comprising said agonist and said second region comprising said antagonist.

### Claim 25 (depends on 19)

The composition of claim 19, wherein said agonist has a local pH of about 4 to about 9.

### Claim 26 (depends on 19)

The composition of claim 19, wherein said antagonist has a local pH of about 2 to about 4.

### Claim 27

A method of treatment, comprising the steps of:
a. Providing a film dosage composition comprising:
i. A polymeric carrier matrix;
ii. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof; and
iii. A buffer in an amount sufficient to maximize the absorption of said agonist;
iv. A chelator or an antioxidant; and
b. Administering said film dosage composition to a patient.

### Claim 28 (depends on 27)

The method of claim 27, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 29 (depends on 27)

The method of claim 27, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 30 (depends on 27)

The method of claim 27, wherein said agonist is a partial agonist.

### Claim 31 (depends on 27)

The method of claim 27, wherein said agonist is an opioid agonist.

### Claim 32 (depends on 27)

The method of claim 27, wherein said agonist has a local pH of about 4 to about 9.

### Claim 33 (depends on 27)

The method of claim 27, wherein said agonist has a local pH of about 5.5.

### Claim 34 (depends on 27)

The method of claim 27, wherein said composition further comprises a therapeutically effective amount of an antagonist or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 32)

The method of claim 32, wherein said antagonist has a local pH of about 2 to about 4.

### Claim 36 (depends on 27)

The method of claim 27, wherein said film dosage composition is administered to the user through a mucosal membrane of said patient.

### Claim 37 (depends on 36)

The method of claim 36, wherein said film dosage composition remains in the mucosal membrane of said patient for a period of at least 1 minute.

### Claim 38

A method of treatment, comprising the steps of:
a. Providing a film dosage composition comprising:
i. A polymeric carrier matrix;
ii. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof;
iii. A therapeutically effective amount of an antagonist or a pharmaceutically acceptable salt thereof;
iv. A first buffer in an amount sufficient to obtain a local pH of said agonist of about 4 to about 9;
v. A second buffer in an amount sufficient to obtain a local pH of said antagonist of about 2 to about 4;
vi. A chelator or an antioxidant; and
b. Administering said film dosage composition to a user.

### Claim 39 (depends on 38)

The method of claim 38, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 40 (depends on 38)

The method of claim 38, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 41 (depends on 38)

The method of claim 38, wherein said composition comprises a first and a second region, wherein said first region comprises said agonist and said second region comprises said antagonist.

### Claim 42 (depends on 38)

The method of claim 38, wherein said agonist is a partial agonist.

### Claim 43 (depends on 38)

The method of claim 38, wherein said agonist is an opioid agonist.

### Claim 44

A self-supporting film dosage composition comprising:
a. A first region comprising:
i. A first polymeric matrix;
ii. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof; and
iii. A first buffering system in an amount sufficient to optimize the absorption of said agonist;
b. A second region comprising:
i. A second polymeric matrix;
ii. A therapeutically effective amount of an antagonist;
iii. A second buffering system in an amount sufficient to inhibit the absorption of said antagonist; and
iv. A chelator or an antioxidant.

### Claim 45 (depends on 43)

The composition of claim 43, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 46 (depends on 44)

The composition of claim 44, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 47 (depends on 44)

The composition of claim 44, wherein said agonist is a partial agonist.

### Claim 48 (depends on 44)

The composition of claim 44, wherein said agonist is an opioid agonist.

### Claim 49 (depends on 44)

The composition of claim 44, wherein said first buffering system is present in an amount sufficient to provide a local pH of said first region of from about 4 to about 9.

### Claim 50 (depends on 44)

The composition of claim 44, wherein said first buffering system is present in an amount sufficient to provide a local pH of said first region of about 5.5.

### Claim 51 (depends on 44)

The composition of claim 44, wherein said second buffering system is present in an amount sufficient to provide a local pH of said second region of from about 2 to about 4.

### Claim 52 (depends on 44)

The composition of claim 44, wherein said second region is coated onto at least one surface of said first region.

### Claim 53 (depends on 44)

The composition of claim 44, wherein said second region is laminated to at least one surface of said first region.

### Claim 54 (depends on 107)

The composition of claim 107, wherein said first and second region are in a side-by-side arrangement.

### Claim 55

A self-supporting film dosage composition comprising:
a. A polymeric carrier matrix;
b. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof;
c. A therapeutically effective amount of an antagonist or a pharmaceutically acceptable salt thereof;
d. A buffering system sufficient to obtain a local pH of said antagonist of about 2 to about 4; and
e. A chelator or an antioxidant.

### Claim 56

A self-supporting film dosage composition comprising:
a. A polymeric carrier matrix;
b. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof;
c. A therapeutically effective amount of an antagonist or a pharmaceutically acceptable salt thereof;
d. A buffering system sufficient to inhibit absorption of said antagonist and optimize absorption of said agonist when said film dosage composition is placed in the mouth of a user; and
e. A chelator or an antioxidant.

### Claim 57

A self-supporting film dosage composition comprising:
a. A first region comprising:
i. A first polymeric matrix;
ii. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof; and
iii. A first buffering system in an amount sufficient to optimize absorption of said agonist when said film dosage composition is placed in the mouth of a user; and
b. A second region comprising:
i. A second polymeric matrix;
ii. A therapeutically effective amount of an antagonist;
iii. A second buffering system in an amount sufficient to inhibit absorption of said antagonist when said film dosage composition is placed in the mouth of a user; and
iv. A chelator or an antioxidant.

### Claim 58 (depends on 57)

The composition of claim 57, wherein said first and second buffering systems are the same.

### Claim 59

A process of forming a film dosage composition comprising the steps of:
a. Casting a film-forming composition, said film-forming composition comprising:
i. A polymeric carrier matrix;
ii. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof;
iii. A therapeutically effective amount of an antagonist or a pharmaceutically acceptable salt thereof;
iv. A buffer in an amount sufficient to optimize absorption of said agonist and sufficient to inhibit absorption of said antagonist when said film dosage composition is placed in the mouth of a user; and
v. A chelator or an antioxidant; and
b. Drying said film-forming composition to form a self-supporting film dosage composition.

### Claim 60

A method of treatment, comprising the steps of:
a. Providing a film dosage composition comprising:
i. A polymeric carrier matrix;
ii. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof;
iii. A therapeutically effective amount of an antagonist or a pharmaceutically acceptable salt thereof;
iv. A buffering system in an amount sufficient to provide an in vivo plasma profile having a Cmax of about 0.624-5.638 ng/ml for said agonist and an in vivo plasma profile having a Cmax of about 41.04-323.75 pg/ml for said antagonist; and
v. A chelator or an antioxidant; and
b. Administering said film dosage composition to a user.

### Claim 61

A self-supporting film dosage composition comprising:
a. A first region comprising:
i. A first polymeric matrix;
ii. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof; and
iii. A first buffering system in an amount sufficient to optimize the absorption of said agonist;
b. A second region comprising:
i. A second polymeric matrix;
ii. A therapeutically effective amount of an antagonist;
iii. A second buffering system in an amount sufficient to inhibit the absorption of said antagonist; and
iv. A chelator or an antioxidant;
wherein said second region dissolves at a faster rate when placed in the oral cavity of the user than said first region.

### Claim 62 (depends on 61)

The composition of claim 61, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 63 (depends on 61)

The composition of claim 61, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 64 (depends on 61)

The composition of claim 61, wherein said first polymeric matrix comprises a moderate-dissolving polymer.

### Claim 65 (depends on 61)

The composition of claim 61, wherein said second polymeric matrix comprises a fast-dissolving polymer.

### Claim 66 (depends on 61)

The composition of claim 61, wherein said first buffering system is sufficient to provide a local pH for said agonist of from about 4 to about 9.

### Claim 67 (depends on 61)

The composition of claim 61, wherein said second buffering system is sufficient to provide a local pH for said antagonist of from about 2 to about 4.

### Claim 68

A process of forming a film dosage composition comprising the steps of:
a. Casting a first film-forming composition, said first film-forming composition comprising:
i. A polymeric carrier matrix;
ii. A therapeutically effective amount of an agonist or a pharmaceutically acceptable salt thereof; and
iii. A buffer in an amount sufficient to optimize absorption of said agonist when said film dosage composition is placed in the mouth of a user;
b. Casting a second film-forming composition, said second film-forming composition comprising:
i. A polymeric carrier matrix;
ii. A therapeutically effective amount of an antagonist or a pharmaceutically acceptable salt thereof; and
iii. A buffer in an amount sufficient to inhibit absorption of said antagonist when said film dosage composition is placed in the mouth of a user;
iv. A chelator or an antioxidant; and
c. Combining said first film-forming composition and said second film-forming composition together to form a self-supporting film dosage composition.

### Claim 69 (depends on 68)

The process of claim 68, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 70 (depends on 68)

The process of claim 68, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 71 (depends on 68)

The process of claim 68, wherein said first film-forming composition is dried prior to said step of combining said first film-forming composition and said second film-forming composition together.

### Claim 72 (depends on 68)

The process of claim 68, wherein said second film-forming composition is dried prior to said step of combining said first film-forming composition and said second film-forming composition together.

### Claim 73 (depends on 68)

The process of claim 68, wherein said first film-forming composition is at least partially dried prior to said step of combining said first film-forming composition and said second film-forming composition together.

### Claim 74 (depends on 68)

The process of claim 68, wherein said second film-forming composition is at least partially dried prior to said step of combining said first film-forming composition and said second film-forming composition together.

### Claim 75

A film dosage composition comprising:
a. a polymeric carrier matrix;
b. a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof;
c. a buffer sufficient to maximize the absorption of the buprenorphine or a pharmaceutically acceptable salt thereof;
d. a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and
e. a chelator or an antioxidant.

### Claim 76 (depends on 75)

The composition of claim 75, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 77 (depends on 75)

The composition of claim 75, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 78 (depends on 75)

The composition of claim 75, wherein said composition has a local pH of about 4 to about 9.

### Claim 79 (depends on 75)

The composition of claim 75, wherein said composition comprises a first and a second region, said first region comprising said buprenorphine or a pharmaceutically acceptable salt thereof and said second region comprising said naloxone or a pharmaceutically acceptable salt thereof.

### Claim 80 (depends on 79)

The composition of claim 79, wherein said first region has a local pH of about 4 to about 9.

### Claim 81 (depends on 80)

The composition of claim 80, wherein said local pH is about 5.5.

### Claim 82 (depends on 79)

The composition of claim 79, wherein said second region has a local pH of about 2 to about 4.

### Claim 83 (depends on 82)

The composition of claim 82, wherein said local pH is about 2.

### Claim 84 (depends on 75)

The composition of claim 75, wherein said polymeric carrier matrix comprises at least one polymer in an amount of at least 25% by weight of said composition.

### Claim 85 (depends on 75)

The composition of claim 75, wherein said buffer is present in an amount of from about 2:1 to about 1:5 buffer to agonist.

### Claim 86 (depends on 75)

The composition of claim 75, wherein said composition comprises at least one self-supporting film-forming polymer.

### Claim 87 (depends on 75)

The film dosage composition of claim 75, wherein said agonist is present in an amount of from about 2 mg to about 16 mg per dosage.

### Claim 88 (depends on 75)

The film dosage composition of claim 75, wherein said buffer comprises sodium citrate, citric acid, and combinations thereof.

### Claim 89 (depends on 75)

The film dosage composition of claim 75, wherein said buffer comprises acetic acid, sodium acetate, and combinations thereof.

### Claim 90 (depends on 75)

The film dosage composition of claim 75, wherein said chelator is present in an amount sufficient to inhibit the oxidation of said naloxone or a pharmaceutically acceptable salt thereof.

### Claim 91 (depends on 77)

The film dosage composition of claim 77, wherein said EDTA is present in an amount sufficient to inhibit the oxidation of said naloxone or a pharmaceutically acceptable salt thereof.

### Claim 92 (depends on 77)

The film dosage composition of claim 77, wherein said EDTA is present in an amount of about 1 to about 7.5% by weight of the total film dosage composition.

### Claim 93 (depends on 77)

The film dosage composition of claim 77, wherein said EDTA is present in an amount of about 1 to about 2% by weight of the total film dosage composition.

### Claim 94 (depends on 77)

The film dosage composition of claim 77, wherein the weight ratio of said naloxone or a pharmaceutically acceptable salt thereof to said EDTA is about from about 0.5:2 to about 2:0.5.

### Claim 95 (depends on 77)

The film dosage composition of claim 77, wherein the weight ratio of said naloxone or a pharmaceutically acceptable salt thereof to said EDTA is about from about 1:2 to about 2:1.

### Claim 96

A method of treatment, comprising the steps of:
a. Providing a film dosage composition comprising:
i. a polymeric carrier matrix;
ii. a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof;
iii. a buffer sufficient to maximize the absorption of the buprenorphine or a pharmaceutically acceptable salt thereof;
iv. a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and
v. a chelator or an antioxidant; and
b. Administering said film dosage composition to a patient.

### Claim 97 (depends on 96)

The composition of claim 96, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 98 (depends on 96)

The composition of claim 96, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 99 (depends on 96)

The method of claim 96, wherein said buprenorphine or a pharmaceutically acceptable salt thereof has a local pH of about 4 to about 9.

### Claim 100 (depends on 96)

The method of claim 96, wherein said naloxone or a pharmaceutically acceptable salt thereof has a local pH of about 2 to about 4.

### Claim 101 (depends on 96)

The method of claim 96, wherein said film dosage composition is administered to the user through a mucosal membrane of said patient.

### Claim 102 (depends on 96)

The method of claim 96, wherein said film dosage composition remains in the mucosal membrane of said patient for a period of at least 1 minute.

### Claim 103 (depends on 96)

The film dosage composition of claim 96, wherein said chelator is present in an amount sufficient to inhibit the oxidation of said naloxone or a pharmaceutically acceptable salt thereof.

### Claim 104 (depends on 98)

The film dosage composition of claim 98, wherein said EDTA is present in an amount sufficient to inhibit the oxidation of said naloxone or a pharmaceutically acceptable salt thereof.

### Claim 105 (depends on 98)

The film dosage composition of claim 98, wherein said EDTA is present in an amount of about 1 to about 7.5% by weight of the total film dosage composition.

### Claim 106 (depends on 98)

The film dosage composition of claim 98, wherein said EDTA is present in an amount of about 1 to about 2% by weight of the total film dosage composition.

### Claim 107 (depends on 98)

The film dosage composition of claim 98, wherein the weight ratio of said naloxone or a pharmaceutically acceptable salt thereof to said EDTA is about from about 0.5:2 to about 2:0.5.

### Claim 108 (depends on 98)

The film dosage composition of claim 98, wherein the weight ratio of said naloxone or a pharmaceutically acceptable salt thereof to said EDTA is about from about 1:2 to about 2:1.

### Claim 109

A film dosage composition comprising:
a. A first region comprising:
i. A first polymeric matrix;
ii. A therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof; and
iii. A first buffering system in an amount sufficient to optimize the absorption of said buprenorphine or a pharmaceutically acceptable salt thereof;
b. A second region comprising:
i. A second polymeric matrix;
ii. A therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof;
iii. A second buffering system in an amount sufficient to inhibit the absorption of said naloxone or a pharmaceutically acceptable salt thereof; and
iv. A chelator or an antioxidant.

### Claim 110 (depends on 109)

The composition of claim 109, wherein said chelator is selected from the group consisting of ethylenediamineeteraacetic acid and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof.

### Claim 111 (depends on 109)

The composition of claim 109, wherein said chelator is ethylenediaminetetraacetic acid disodium salt (EDTA).

### Claim 112 (depends on 109)

The composition of claim 109, wherein said first buffering system is present in an amount sufficient to provide a local pH of said first region of from about 4 to about 9.

### Claim 113 (depends on 109)

The composition of claim 109, wherein said first buffering system is present in an amount sufficient to provide a local pH of said first region of about 5.5.

### Claim 114 (depends on 109)

The composition of claim 109, wherein said second buffering system is present in an amount sufficient to provide a local pH of said second region of from about 2 to about 4.

### Claim 115 (depends on 109)

The composition of claim 109, wherein said second region is coated onto at least one surface of said first region.

### Claim 116 (depends on 109)

The composition of claim 109, wherein said second region is laminated to at least one surface of said first region.

### Claim 117 (depends on 109)

The composition of claim 109, wherein said first and second region are in a side-by-side arrangement.

### Claim 118 (depends on 109)

The film dosage composition of claim 109, wherein said chelator is present in an amount sufficient to inhibit the oxidation of said naloxone or a pharmaceutically acceptable salt thereof.

### Claim 119 (depends on 111)

The film dosage composition of claim 111, wherein said EDTA is present in an amount sufficient to inhibit the oxidation of said naloxone or a pharmaceutically acceptable salt thereof.

### Claim 120 (depends on 111)

The film dosage composition of claim 111, wherein said EDTA is present in an amount of about 1 to about 7.5% by weight of the second region.

### Claim 121 (depends on 111)

The film dosage composition of claim 111, wherein said EDTA is present in an amount of about 1 to about 2% by weight of the second region.

### Claim 122 (depends on 111)

The film dosage composition of claim 111, wherein the weight ratio of said naloxone or a pharmaceutically acceptable salt thereof to said EDTA is about from about 0.5:2 to about 2:0.5.

### Claim 123 (depends on 111)

The film dosage composition of claim 111, wherein the weight ratio of said naloxone or a pharmaceutically acceptable salt thereof to said EDTA is about from about 1:2 to about 2:1.

### Claim 124

A process of forming a film dosage composition comprising the steps of:
a. Casting a film-forming composition, said film-forming composition comprising:
i. A polymeric carrier matrix;
ii. A therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof;
iii. A therapeutically effective amount of an naloxone or a pharmaceutically acceptable salt thereof;
iv. A buffer in an amount sufficient to optimize absorption of said buprenorphine or a pharmaceutically acceptable salt thereof and sufficient to inhibit absorption of said naloxone or a pharmaceutically acceptable salt thereof when said film dosage composition is placed in the mouth of a user; and
v. A chelator or an antioxidant.
b. Drying said film-forming composition to form a self-supporting film dosage composition.

### Claim 125

A self-supporting film dosage composition comprising:
a. A first region comprising:
i. A first polymeric matrix;
ii. A therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof; and
iii. A first buffering system in an amount sufficient to optimize the absorption of said buprenorphine or a pharmaceutically acceptable salt thereof;
b. A second region comprising:
i. A second polymeric matrix;
ii. A therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof;
iii. A second buffering system in an amount sufficient to inhibit the absorption of said naloxone or a pharmaceutically acceptable salt thereof; and
iv. A chelator or an antioxidant;
wherein said second region dissolves at a faster rate when placed in the oral cavity of the user than said first region.

### Claim 126 (depends on 125)

The composition of claim 125, wherein said first polymeric matrix comprises a moderate-dissolving polymer.

### Claim 127 (depends on 125)

The composition of claim 125, wherein said second polymeric matrix comprises a fast-dissolving polymer.

### Claim 128 (depends on 125)

The composition of claim 125, wherein said first buffering system is sufficient to provide a local pH for said agonist of from about 4 to about 9.

### Claim 129 (depends on 125)

The composition of claim 125, wherein said second buffering system is sufficient to provide a local pH for said antagonist of from about 2 to about 4.

### Claim 130

A process of forming a film dosage composition comprising the steps of:
a. Casting a first film-forming composition, said first film-forming composition comprising:
i. A polymeric carrier matrix;
ii. A therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof; and
iii. A buffer in an amount sufficient to optimize absorption of said buprenorphine or a pharmaceutically acceptable salt thereof when said film dosage composition is placed in the mouth of a user;
b. Casting a second film-forming composition, said second film-forming composition comprising:
i. A polymeric carrier matrix;
ii. A therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof;
iii. A buffer in an amount sufficient to inhibit absorption of said naloxone or a pharmaceutically acceptable salt thereof when said film dosage composition is placed in the mouth of a user; and
iv. A chelator or an antioxidant; and
c. Combining said first film-forming composition and said second film-forming composition together to form a self-supporting film dosage composition.

### Claim 131 (depends on 130)

The process of claim 130, wherein said first film-forming composition is dried prior to said step of combining said first film-forming composition and said second film-forming composition together.

### Claim 132 (depends on 130)

The process of claim 130, wherein said second film-forming composition is dried prior to said step of combining said first film-forming composition and said second film-forming composition together.

### Claim 133 (depends on 130)

The process of claim 130, wherein said first film-forming composition is at least partially dried prior to said step of combining said first film-forming composition and said second film-forming composition together.

### Claim 134 (depends on 130)

The process of claim 130, wherein said second film-forming composition is at least partially dried prior to said step of laminating said first film-forming composition and said second film-forming composition together.

### Claim 135 (depends on 1)

The composition of claim 1, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 136 (depends on 1)

The composition of claim 1, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 137 (depends on 136)

The composition of claim 136, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 138 (depends on 1)

The composition of claim 1, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 139 (depends on 138)

The composition of claim 138, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 140 (depends on 19)

The composition of claim 19, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 141 (depends on 19)

The composition of claim 19, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 142 (depends on 141)

The composition of claim 141, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 143 (depends on 19)

The composition of claim 19, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 144 (depends on 141)

The composition of claim 141, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 145 (depends on 27)

The method of claim 27, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 146 (depends on 27)

The method of claim 27, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 147 (depends on 146)

The method of claim 146, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 148 (depends on 27)

The method of claim 27, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 149 (depends on 148)

The composition of claim 148, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 150 (depends on 38)

The method of claim 38, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 151 (depends on 38)

The method of claim 38, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 152 (depends on 151)

The method of claim 151, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 153 (depends on 38)

The method of claim 38, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 154 (depends on 153)

The composition of claim 153, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 155 (depends on 44)

The composition of claim 44, wherein the second region contains a chelator and no antioxidant.

### Claim 156 (depends on 44)

The composition of claim 44, wherein the second region contains both a chelator and an antioxidant.

### Claim 157 (depends on 156)

The composition of claim 156, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 158 (depends on 44)

The composition of claim 44, wherein the second region contains an antioxidant and no chelator.

### Claim 159 (depends on 158)

The composition of claim 158, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 160 (depends on 55)

The composition of claim 55, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 161 (depends on 55)

The composition of claim 55, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 162 (depends on 161)

The composition of claim 161, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 163 (depends on 55)

The composition of claim 55, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 164 (depends on 163)

The composition of claim 163, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 165 (depends on 56)

The composition of claim 56, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 166 (depends on 56)

The composition of claim 56, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 167 (depends on 166)

The composition of claim 166, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 168 (depends on 56)

The composition of claim 56, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 169 (depends on 168)

The composition of claim 168, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 170 (depends on 57)

The composition of claim 57, wherein the second region contains a chelator and no antioxidant.

### Claim 171 (depends on 57)

The composition of claim 57, wherein the second region contains both a chelator and an antioxidant.

### Claim 172 (depends on 172)

The composition of claim 172, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 173 (depends on 57)

The composition of claim 57, wherein the second region contains an antioxidant and no chelator.

### Claim 174 (depends on 173)

The composition of claim 173, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 175 (depends on 59)

The method of claim 59, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 176 (depends on 59)

The method of claim 59, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 177 (depends on 176)

The method of claim 176, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 178 (depends on 59)

The method of claim 59, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 179 (depends on 178)

The method of claim 178, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 180 (depends on 60)

The method of claim 60, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 181 (depends on 60)

The method of claim 60, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 182 (depends on 181)

The method of claim 181, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 183 (depends on 60)

The method of claim 60, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 184 (depends on 183)

The method of claim 183, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 185 (depends on 61)

The method of claim 61, wherein the second region contains a chelator and no antioxidant.

### Claim 186 (depends on 61)

The method of claim 61, wherein the second region contains both a chelator and an antioxidant.

### Claim 187 (depends on 186)

The method of claim 186, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 188 (depends on 61)

The method of claim 61 wherein the second region contains an antioxidant and no chelator.

### Claim 189 (depends on 188)

The method of claim 188, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 190 (depends on 68)

The process of claim 68, wherein the second film-forming composition contains a chelator and no antioxidant.

### Claim 191 (depends on 68)

The process of claim 68, wherein the second film-forming composition contains both a chelator and an antioxidant.

### Claim 192 (depends on 191)

The process of claim 191, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 193 (depends on 68)

The process of claim 68 wherein the second film-forming composition contains an antioxidant and no chelator.

### Claim 194 (depends on 193)

The process of claim 193, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 195 (depends on 75)

The composition of claim 75, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 196 (depends on 75)

The composition of claim 75, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 197 (depends on 196)

The composition of claim 196, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 198 (depends on 75)

The composition of claim 75, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 199 (depends on 198)

The composition of claim 198, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 200 (depends on 96)

The method of claim 96, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 201 (depends on 96)

The method of claim 96, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 202 (depends on 201)

The method of claim 201, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 203 (depends on 96)

The method of claim 96, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 204 (depends on 203)

The method of claim 203, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 205 (depends on 109)

The composition of claim 109, wherein the second region contains a chelator and no antioxidant.

### Claim 206 (depends on 109)

The composition of claim 109, wherein the second region contains both a chelator and an antioxidant.

### Claim 207 (depends on 206)

The composition of claim 206, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 208 (depends on 109)

The composition of claim 109, wherein the second region contains an antioxidant and no chelator.

### Claim 209 (depends on 208)

The composition of claim 208, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 210 (depends on 124)

The process of claim 124, wherein the self-supporting film dosage composition contains a chelator and no antioxidant.

### Claim 211 (depends on 124)

The process of claim 124, wherein the self-supporting film dosage composition contains both a chelator and an antioxidant.

### Claim 212 (depends on 212)

The process of claim 212, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 213 (depends on 124)

The process of claim 124, wherein the self-supporting film dosage composition contains an antioxidant and no chelator.

### Claim 214 (depends on 213)

The process of claim 213, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 215 (depends on 125)

The composition of claim 125, wherein the second region contains a chelator and no antioxidant.

### Claim 216 (depends on 125)

The composition of claim 125, wherein the second region contains both a chelator and an antioxidant.

### Claim 217 (depends on 216)

The composition of claim 216, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 218 (depends on 125)

The composition of claim 125, wherein the second region contains an antioxidant and no chelator.

### Claim 219 (depends on 218)

The composition of claim 218, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 220 (depends on 130)

The process of claim 130, wherein the second film-forming composition contains a chelator and no antioxidant.

### Claim 221 (depends on 130)

The process of claim 130, wherein the second film-forming composition contains both a chelator and an antioxidant.

### Claim 222 (depends on 221)

The process of claim 221, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.

### Claim 223 (depends on 130)

The process of claim 130 wherein the second film-forming composition contains an antioxidant and no chelator.

### Claim 224 (depends on 223)

The process of claim 223, wherein the antioxidant is selected from the groups consisting of dibutylhydroxytoluene, dibutylated hydroxyanisole, propyl gallate, sodium sulfate, citric acid, sodium metabusulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole and combination thereof.
